FibroBiologics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 16.49 million compared to USD 5.12 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 0.18 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.11 USD | -0.97% | -25.86% | 0.00% |
Jun. 13 | FibroBiologics to Join Russell 2000 Index in July | MT |
May. 14 | FibroBiologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 233M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- FBLG Stock
- News FibroBiologics, Inc.
- FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023